Literature DB >> 27380217

Molecular dynamics-based identification of novel natural mortalin-p53 abrogators as anticancer agents.

Neha Nagpal1, Sukriti Goyal1, Jaspreet Kaur Dhanjal1, Liu Ye2, Sunil C Kaul2, Renu Wadhwa2, Rupesh Chaturvedi1, Abhinav Grover1.   

Abstract

INTRODUCTION: Cancer is one of the leading causes of mortality worldwide that requires attention in terms of extensive study and research. Eradication of mortalin-p53 interaction that leads to the inhibition of transcriptional activation or blocking of p53 from functioning as a suppressor and induction of nuclear translocation of p53 can prove to be one of the useful approaches for cancer management.
RESULTS: In this study, we used structure-based approach to target the p53-binding domain of mortalin in order to prevent mortalin-p53 complex formation. We screened compounds from ZINC database against the modeled mortalin protein using Glide virtual screening. The top two compounds, DTOM (ZINC 28639308) and TTOM (ZINC 38143676) with Glide score of -12.27 and -12.16, respectively, were identified with the potential to abrogate mortalin-p53 interaction. Finally, molecular dynamics simulations were used to analyze the dynamic stability of the ligand-bound complex and it was observed that residues Tyr196, Asn198, Val264 and Thr267 were involved in intermolecular interactions in both the simulated ligand-bound complexes, and thus, these residues may have a paramount role in stabilizing the binding of the ligands with the protein.
CONCLUSION: These detailed insights can further facilitate the development of potent inhibitors against mortalin-p53 complex.

Entities:  

Keywords:  Cancer; inhibitor; molecular dynamics; mortalin; natural; p53

Mesh:

Substances:

Year:  2016        PMID: 27380217     DOI: 10.3109/10799893.2016.1141952

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  3 in total

Review 1.  Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far.

Authors:  Ahmed Elwakeel
Journal:  Front Cell Dev Biol       Date:  2022-04-14

2.  Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.

Authors:  Sharad Verma; Sukriti Goyal; Anchala Kumari; Aditi Singh; Salma Jamal; Abhinav Grover
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

3.  Salvianolic acid B targets mortalin and inhibits the migration and invasion of hepatocellular carcinoma via the RECK/STAT3 pathway.

Authors:  Mengying Teng; Chunyan Hu; Bingmo Yang; Wei Xiao; Qian Zhou; Yuan Li; Zhong Li
Journal:  Cancer Cell Int       Date:  2021-12-07       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.